SCHEMBL23917850

SCHEMBL23917850

CC(C)(C)c1nc(-c2ccc(Cl)cc2)no1

nearest known ligand 0.59

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NR1H4 Q96RI1 1/20 0.56
NOTUM Q6P988 2/20 0.51
NPC1 O15118 2/20 0.51
RAB9A P51151 2/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
HDAC4 P56524 1/20 0.49
HDAC6 Q9UBN7 1/20 0.49
TSHR P16473 1/20 0.49
CYP1A2 P05177 1/20 0.49
CASP3 P42574 5/20 0.49
SENP8 Q96LD8 1/20 0.49
SENP7 Q9BQF6 1/20 0.49
SENP6 Q9GZR1 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
AOC3 Q16853 2/20 0.47
ALDH1A1 P00352 1/20 0.47
SIRT2 Q8IXJ6 2/20 0.46
KMT2A Q03164 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31375602 0.84 NPC1 (0.54) NR1H4NPC1RAB9ASMN1; SMN2HDAC4
SCHEMBL17377373 0.84 NOTUM (0.53) NR1H4NOTUMNPC1RAB9ASMN1; SMN2
SCHEMBL5648596 0.82 NR1H4 (0.54) NR1H4NPC1RAB9ASMN1; SMN2HDAC4
SCHEMBL6497959 0.82 AOC3 (0.50) NOTUMNPC1RAB9AHDAC4HDAC6
SCHEMBL21889831 0.82 AOC3 (0.50) NPC1RAB9ASMN1; SMN2HDAC4HDAC6
SCHEMBL77622 0.81 NR1H4 (0.57) NR1H4NOTUMNPC1RAB9ASMN1; SMN2
SCHEMBL25914437 0.81 TSHR (0.52) NR1H4NOTUMNPC1RAB9ASMN1; SMN2
SCHEMBL25914360 0.81 TSHR (0.55) NR1H4NOTUMNPC1RAB9ASMN1; SMN2
SCHEMBL14153764 0.81 NPC1 (0.54) NPC1RAB9ASMN1; SMN2HDAC4HDAC6
SCHEMBL2567937 0.80 HDAC6 (0.54) NPC1RAB9ASMN1; SMN2HDAC4HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240239776-A1 AZASPIROCYCLES AS MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2024-07-18 US disclosed
US-20230331686-A1 AMINOCYCLOBUTANES AS MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2023-10-19 US disclosed
US-20230331686-A1 AMINOCYCLOBUTANES AS MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2023-10-19 US disclosed
US-11787798-B2 Aryl piperidines as monoacylglycerol lipase modulators JANSSEN PHARMACEUTICA NV (BE) 2023-10-17 US disclosed
US-11787798-B2 Aryl piperidines as monoacylglycerol lipase modulators JANSSEN PHARMACEUTICA NV (BE) 2023-10-17 US disclosed
US-20220081428-A1 AZASPIROCYCLES AS MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2022-03-17 US disclosed
US-20210317094-A1 AMINOCYCLOBUTANES AS MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2021-10-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240239776-A1 AZASPIROCYCLES AS MONOACYLGLYCEROL LIPASE MODULATORS MGLL, LPL, LPAR1 NR1H4 1625/4885NOTUM 2013/4885NPC1 872/4885
US-11787798-B2 Aryl piperidines as monoacylglycerol lipase modulators MGLL, LPL, PNLIP NR1H4 2103/4885NOTUM 1643/4885NPC1 955/4885
US-20230331686-A1 AMINOCYCLOBUTANES AS MONOACYLGLYCEROL LIPASE MODULATORS MGLL, DAGLB, FAAH NR1H4 1471/4885NOTUM 1201/4885NPC1 1700/4885
US-20210317094-A1 AMINOCYCLOBUTANES AS MONOACYLGLYCEROL LIPASE MODULATORS MGLL, DAGLB, FAAH NR1H4 1471/4885NOTUM 1201/4885NPC1 1700/4885
US-20220081428-A1 AZASPIROCYCLES AS MONOACYLGLYCEROL LIPASE MODULATORS MGLL, LPAR1, LPL NR1H4 1664/4885NOTUM 2079/4885NPC1 884/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.